Szilárd Kiss, MD


Perspectives on intravenous bevacizumab repackaged for intravitreal use

June 15, 2022

Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.